Drug-induced Liver Injury: Development of a MILLIPLEX® MAP Multiplexed Assay Panel for Emerging Biomarkers

Drug-induced liver injury (DILI) is an adverse event that results in withdrawal of drugs from market. As drugs may cause liver injury through various mechanisms, measuring multiple biomarkers is required to determine the potential for hepatotoxicity in early drug development. EMD Millipore’s MILLIPLEX® MAP Rat Liver Injury Panel can measure PSTC-investigated hepatotoxicity enzyme biomarkers simultaneously. In addition, because cytokines have been under investigation as potential DILI biomarkers, we used MILLIPLEX® MAP Rat Cytokine/Chemokine Panel to measure 27 cytokines and found that changes in 8 cytokines paralleled changes in hepatocellular enzyme biomarkers.